top of page
Hansoh’s HS-10374 meets primary endpoints in P3 psoriasis
Hansoh
23/09/26
Hansoh Pharma announced that HS-10374, allosteric inhibitor of tyrosine kinase (TYK2), met its primary endpoints in its pivotal Phase 3 study to treat moderate-to-severe psoriasis in adults. At 16 weeks patients showed a statistically significant improvement over placebo with both the PASI (Posriasis Area and Severity Index) and sPGA (static Physician’s Global Assessment) endpoints. Statistical significance in PASI is considered a 75% reduction over baseline (PASI 75); more than half of patients on HS-10374 achieved PASI 90, and one third PASI 100 at week 16. Based on these data Hansoh will advance its communications with China’s NMPA to seek regulatory approval.
Hengrui receives go-ahead on triplet of clinical trials
Hengrui
22/09/26
Hengrui has recevied regulatory approval for three clinical programmes. Firstly, for HRS-4729 polypeptide injectable, triple GLP-1R, GIPR, and GCGR agonist for the treatment of chronic kidney disease. The company proposes that, weight loss, improved insulin resistance and reduction in ectopic fat, would reduce metabolic burden on the kidneys. Secondly, SHR-4595 is an injectable to treat advanced malignant solid tumours by binding to known tumour-cell surface antigens. Finally, HRS-1596 tablets for weight management and type 2 diabetes. The asset showed weight loss and improved blood glucose indicators in animal models of obesity and diabetes. The company believes this to be the first orally available asset to be hitting this known (but undisclosed) target.
BioKin triggers USD250m milestone in BMS deal
BioKin Pharma
22/09/26
BioKin (Baili Tianheng) clinical progress has triggered the next USD250m milestone payment in its collaboration with BMS. The deal revolves around Izabren (Lencon Ilonutumab; BL-B01D1) in oncology. The asset has reached an undisclosed milestone in the IZABRIGHT-Lung02 global Phase 3 study. BioKen is eligible to up to USD7.1bn in future payments contingent on development, registration, and sales milestones.
BoomRay signs USD900m Radioligand deal with Novartis
BoomRay
22/09/26
BoomRay Pharmaceuticals has entered an exclusive global licensing deal with Novartis for an undisclosed pre-clinical radioligand therapy (RLT) asset for oncology applications. Under the agreement, BoomRay is eligible to receive up to USD900m in upfront, development, regulatory and sales milestone payments; plus potential royalties on global sales. BoomRay has a pipeline of clinical and preclinical RLT programmes, which combine a radio-isotope with a tumour binding ligand. The company proposes that the RLT mechanism of action is less susceptible to drug resistance, as the cytotoxic effect is not dependent on cellular uptake or active transport pathways.
Accro aims high with P2b study in UC
Accro Bioscience
21/09/26
Accro Bio has dosed its first patient in a Phase 2b study of AC-101 (a selective RIPK2 inhibitor) to treat moderate-to-severe ulcerative colitis. The study is a multi-centre, double-blind, trial with two AC-101 cohorts against one placebo-controlled. The primary endpoint is clinical remission at week 12; with exploratory endpoints of histological remission, and maintenance of histological and clinical remission over long-term treatment.
CSPC starts P2 Type-2 diabetes weight-loss study
CSPC Pharma
16/09/26
CSPC has started patient recruitment into its Phase 2 study of SYH2069 injection to treat Type-2 diabetes mellitus. SYH2069 is a fatty acid-modified polypeptide, and dual agonist of GLP-1R and GIPR. The product is designed to promote insulin secretion, but also expected to suppress appetite, delay gastric emptying, increase satiation relating to weight-loss effects.
IASO208 CAR-T receives FDA IND clearance
IASO Bio
16/09/26
The US FDA has cleared the IND for IASO208 CD20-targeting CAR-T therapy. IASO208 uses a lentivial vector to deliver humanised anti-CD20 CAR transgene, to generate anti-CD20 CAR-T cells. IASO208 is currently in a Phase 1 study in China to assess safety, tolerability, and early efficacy in patients with relapsed/refractory B-cell malignancies.
Chimagen sells oncology trispecific to GSK for USD750m
Chimagen
15/09/26
GSK has acquired the global rights to Chimagen’s trispecfic T cell-engager to treat multiple myeloma for up to USD750m in upfront, development and commercial milestone payments. The asset is engineered to bind to T cells plus two strategically selected tumour-associated antigens. GSK plans to take the product in the Phase 1 trials in 2027.
Kelun publishes P3 data in JCO
Kelun-Biotech
14/09/26
Results from Kelun’s Phase 3 study of trastuzumab botidotin to treat HER-2 positive unresectable or metastatic breast cancer are now published in the Journal of Clinical Oncology (JCO). The study showed that trastuzumab botidotin monotherapy significantly prolonged progression free survival over trastuzumab emtansine.
MediLink lung cancer drug significantly extends overall survival
MediLink
13/09/26
Tambotatug Pelitecan (Tam-Peli), an anti-B7-H3 ADC from MediLink, met its primary endpoint of overall survival, and demonstrated a 54% reduction in the risk of death. Tam-Peli also significantly extended progression free survival. The new data was generated in a P3 study of Tam-Peli vs Topotecan chemotherapy, in small cell lung cancer patients that had disease progression following platinum-based chemo. The trial enrolled 451 patients across 85 sites in China. Roche has exclusive commercialisation rights to Tam-Peli outside of China, Hong Kong, and Macau.
CMS receives approval for systemic lupus product trial
China Medical Systems
11/09/26
CMS was granted Drug Clinical Trial Approval Notice from China’s NMPA for CMS-D001 to treat systemic lupus erthematosus. CMS-D001 is an oral inhibitor of TYK2, and member of the JAK family. CMS proposes that, compared to pan-JAK inbibitors, CMS-D001 is more selective and has the potential to reduce side effects and without risk of anti-drug antibody formation
OcuMension NDA accepted for NMPA review
OcuMension Therapeutics
11/09/26
OcuMension’s NCX 470 (OT-301), to lower intraocular pressure in patients with open-angel glaucoma or ocular hypertensions, has its NDA accepted for review by the NMPA. OcuMension has commercialisation rights to the product – from Nicox – in China, Korea, and South East Asia.
Adagene partner Third Arc selects first drug candiate
Adagene
10/09/26
Adagene’s partner Third Arc Bio has selected its first antibody drug development candidate from Adagene’s SAFEbody platform. Under an agreement from November 2025, Adagene is providing Masked CD3 T cell antibodies targeting epitopes of tumour-associated antigens.
Positive P2a data on Rifaquizinone for periprosthetic joint infection
TenNor Therapeutics
10/09/26
TenNor’s topline results from its Phase 2a rifaquizinone (TNP-2092) provided proof-of-concept of the product’s potential to treat Periprosthetic Joint Infection (PJI) without surgical intervention. Rifaquizinone is a first-in-class, triple-targeting anti-infective addressing implant-associated biofilm infections.
Transcenta and WuXi Biologics to commercialse bioprocessing tech
Transcenta Therapeutics
09/09/26
Transcenta granted WuXi a non-exclusive license to its bioprocessing platform and cell culture media for RMB10m (USD1.5m). Transcenta has a pipeline of clinical and preclinical stage oncology products, plus products in osteoporosis and other auto-immune diseases
InnoCare IND approved for bispecific for prostate cancer
InnoCare
08/09/26
InnoCare received NMPA (China’s National Medical Products Administration) approval of its IND for ICP-B382, bispecific ADC targeting PSMA and STEAP1 for the treatment of solid tumours including prostate cancer. This is InnoCare’s first bispecific ADC to enter clinical studies. ICP-B381 is targeting PSMA and STEAP1 as they are significantly overexpressed in prostate cancer cells with limited expression in normal tissue, making them highly promising therapeutic targets.
Interim P3 analysis of Ivonescimab shows meaningful benefit in lung cancer
Akeso
03/09/26
Interim data from Akeso’s Phase 3 HARMONi-2 study of ivonescimab PD-1/VEGF bispecific antibody demonstrated a statistically significant and clinically meaningful improvement over Pembrolizumab in non-small cell lung cancer with tumours expressing PD-L1.
Hansoh gets BLA for cancer drug
Hansoh Pharma
09/07/26
Hansoh Pharma says the China National Medical Products Administration (NMPA）has accepted its biologics license application (BLA) for HS-20093（Risvutatug rezetecan, or Ris-Rez）injectable to treat small cell lung cancer (SCLC). Ris-Rez is a B7-H3-targeted antibody-drug conjugate (ADC) under clinical development for multiple solid tumors. The BLA is supported by results from a pivotal Phase 3 clinical trial (ARTEMIS-008) for patients with advanced or relapsed SCLC after prior platinum-based therapy.
bottom of page